A compound of formula characterized in that R5 is linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl or linear or branched C 1 -C 4 aminoalkyl; R6 is halogen; BM is a DNA binding moiety of formula: wherein: X is null or linear or branched C 2 -C 4 alkenyl; Y and Y' are independently an optionally substituted aryl or heteroaryl; U is a moiety of formula or: wherein R3 is hydrogen or a group selected from optionally substituted linear or branched C 1 -C 4 alkyl and C 1 -C 4 hydroxyalkyl; and q is an integer from 0 to 3; L1 is hydrogen or a moiety of formula (Xj) wherein R9 is hydrogen, hydroxy or an optionally substituted group selected from linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl, linear or branched C 1 -C 4 sulfhydrylalkyl and linear or branched C 1 -C 4 aminoalkyl; W1 is null or a system comprising one or more groups selected from the group consisting of and wherein one of R9 and R10 is null and the other is hydrogen, hydroxy or an optionally substituted group selected from linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl, linear or branched C 1 -C 4 sulfhydrylalkyl and linear or branched C 1 -C 4 aminoalkyl; R11 and R12 are, each independently, hydrogen, halogen, linear or branched C 1 -C 4 alkyl or linear or branched C 1 -C 4 hydroxyalkyl; R24 and R25 are, each independently, hydrogen, halogen, methyl, ethyl, linear or branched C 1 -C 4 hydroxyalkyl, linear or branched C 1 -C 4 haloalkyl, or R24 and R25 taken together form a 3 to 6 membered carbocycle; m is an integer from 0 to 3; and A 1 is CH 2, CH 2 N-R13 or N-R13, wherein R13 is hydrogen, linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl or linear or branched C 1 -C 4 haloalkyl; and Z1 is null or a peptidic, non peptidic or hybrid peptidic and non peptidic linker; provided that a compound of formula wherein L1 is hydrogen, R5 is methyl and X is null is excluded when: q is 0 and Y' is a heterocyclyl moiety of formula (VIII), (VIII)' or (VIII)": or q is 1, U is a group of formula as defined above, Y is an heterocyclyl moiety of formula and Y' is an heterocyclyl moiety of formula (VIII)'" wherein Q is NH or O, and R21 is hydrogen or a group selected from -N(C 2 H 5) 2 and -C NH 2 at the position 5 or 6 of the benzene ring; and the pharmaceutically acceptable salts thereof. R5 is linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl or linear or branched C 1 -C 4 aminoalkyl; R6 is halogen; BM is a DNA binding moiety of formula: wherein: X is null or linear or branched C 2 -C 4 alkenyl; Y and Y' are independently an optionally substituted aryl or heteroaryl; U is a moiety of formula or: wherein R3 is hydrogen or a group selected from optionally substituted linear or branched C 1 -C 4 alkyl and C 1 -C 4 hydroxyalkyl; and q is an integer from 0 to 3; X is null or linear or branched C 2 -C 4 alkenyl; Y and Y' are independently an optionally substituted aryl or heteroaryl; U is a moiety of formula or: wherein R3 is hydrogen or a group selected from optionally substituted linear or branched C 1 -C 4 alkyl and C 1 -C 4 hydroxyalkyl; and q is an integer from 0 to 3; L1 is hydrogen or a moiety of formula (Xj) wherein R9 is hydrogen, hydroxy or an optionally substituted group selected from linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl, linear or branched C 1 -C 4 sulfhydrylalkyl and linear or branched C 1 -C 4 aminoalkyl; W1 is null or a system comprising one or more groups selected from the group consisting of one of R9 and R10 is null and the other is hydrogen, hydroxy or an optionally substituted group selected from linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl, linear or branched C 1 -C 4 sulfhydrylalkyl and linear or branched C 1 -C 4 aminoalkyl; R11 and R12 are, each independently, hydrogen, halogen, linear or branched C 1 -C 4 alkyl or linear or branched C 1 -C 4 hydroxyalkyl; R24 and R25 are, each independently, hydrogen, halogen, methyl, ethyl, linear or branched C 1 -C 4 hydroxyalkyl, linear or branched C 1 -C 4 haloalkyl, or R24 and R25 taken together form a 3 to 6 membered carbocycle; m is an integer from 0 to 3; and A 1 is CH 2, CH 2 N-R13 or N-R13, wherein R13 is hydrogen, linear or branched C 1 -C 4 alkyl, linear or branched C 1 -C 4 hydroxyalkyl or linear or branched C 1 -C 4 haloalkyl; and Z1 is null or a peptidic, non peptidic or hybrid peptidic and non peptidic linker; provided that a compound of formula wherein L1 is hydrogen, R5 is methyl and X is null is excluded when: q is 0 and Y' is a heterocyclyl moiety of formula (VIII), (VIII)' or (VIII)": or q is 1, U is a group of formula as defined above, Y is an heterocyclyl moiety of formula and Y' is an heterocyclyl moiety of formula (VIII)'" wherein Q is NH or O, and R21 is hydrogen or a group selected from -N(C 2 H 5) 2 and -C NH 2 at the position 5 or 6 of the benzene ring; and the pharmaceutically acceptable salts thereof.